{"nctId":"NCT03324802","briefTitle":"Hypofractionated Radiation Therapy in Preventing Recurrence in Patients With Breast Cancer After Surgery","startDateStruct":{"date":"2018-02-07","type":"ACTUAL"},"conditions":["Stage I Breast Cancer AJCC v7","Stage IA Breast Cancer AJCC v7","Stage IB Breast Cancer AJCC v7","Stage II Breast Cancer AJCC v6 and v7","Stage IIA Breast Cancer AJCC v6 and v7","Stage IIB Breast Cancer AJCC v6 and v7","Stage IIIA Breast Cancer AJCC v7"],"count":107,"armGroups":[{"label":"Arm 2 (hypofractionated radiation therapy, 5 fractions)","type":"EXPERIMENTAL","interventionNames":["Radiation: Hypofractionated Radiation Therapy","Other: Quality-of-Life Assessment"]},{"label":"Arm I (radiation therapy, 15 fractions)","type":"EXPERIMENTAL","interventionNames":["Other: Quality-of-Life Assessment","Radiation: Radiation Therapy"]}],"interventions":[{"name":"Hypofractionated Radiation Therapy","otherNames":["Hypofractionated Radiotherapy","hypofractionation"]},{"name":"Quality-of-Life Assessment","otherNames":["Quality of Life Assessment"]},{"name":"Radiation Therapy","otherNames":["Cancer Radiotherapy","Irradiate","Irradiated","irradiation","Radiation","Radiotherapeutics","Radiotherapy","RT","Therapy, Radiation"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Histological confirmation of breast cancer\n* Pathologic stage T0-T3N0-N1M0\n* Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 to 2\n* Able to and provides Institutional Review Board (IRB) approved study specific written informed consent\n* Study entry must be within 12 weeks of last surgery (breast or axilla) or last chemotherapy (if applicable)\n* Able to complete all mandatory tests\n* Willing to return to enrolling institution for follow-up (during the active monitoring phase of the study)\n* Fair, good or excellent cosmesis, as determined by trained nurse assessment using the Harvard Cosmetic Scale\n* Radiotherapy must begin within 12 weeks of the last breast cancer surgery or the last dose of adjuvant chemotherapy\n* Breast conserving surgery and indications for whole breast radiotherapy\n\nExclusion Criteria:\n\n* Medical contraindication to receipt of radiotherapy\n* Severe active co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens\n* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements or providing informed consent\n* Active systemic lupus or scleroderma\n* Pregnancy\n* Prior receipt of ipsilateral breast or chest wall radiation\n* Positive margins on ink after definitive surgery either for ductal carcinoma in situ (DCIS) or invasive cancer\n* History of non-breast malignancies (except for in situ cancers treated only by local excision and basal cell and squamous cell carcinomas of the skin) within 5 years prior study entry\n* Recurrent breast cancer\n* Indications for comprehensive regional nodal irradiation","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Complication Rate, Defined as the Percentage of Women Who Develop Grade 3 or Higher Late Adverse Event and/or Deterioration of Cosmesis From Excellent/Good to Fair/Poor or From Fair to Poor","description":"The complication rate will be reported by arm.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]}]},{"type":"SECONDARY","title":"Cause-specific Survival","description":"Will be estimated with a Kaplan-Meier estimator and curve by treatment arm. Estimates will be given for one year with 95% CIs. Comparison between arms will employ a log-rank test.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"100","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Survival","description":"Will be estimated with a Kaplan-Meier estimator and curve by treatment arm. Estimates will be given for one year along with 95% CIs. Comparison between arms will employ a log-rank test.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"100","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Patients Experiencing Distant Recurrence","description":"Distant recurrence defined as metastatic cancer that has either been biopsy confirmed or clinically diagnosed as recurrent invasive breast cancer","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Patients Experiencing Acute (Grade 3+) Adverse Events (AEs)","description":"The maximum grade for each type of acute (grade 3+) AE will be recorded for each patient. Data will be summarized as frequencies and relative frequencies by treatment arm. The relationship of the adverse event(s) to the study treatment will be taken into consideration. Number of patients experiencing one or more grade 3+ events will be compared between arms using chi-squared tests. Adverse events were assessed using the NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.0.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Patients Experiencing Grade 3+ Late Adverse Events","description":"The maximum grade for each type of late AE will be recorded for each patient. Data will be summarized as frequencies and relative frequencies by treatment arm. The relationship of the adverse event(s) to the study treatment will be taken into consideration. Number of patients experiencing one or more grade 3+ late AEs will be compared between arms using chi-squared tests.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]}]},{"type":"SECONDARY","title":"Invasive Disease-free","description":"Will be estimated with a Kaplan-Meier estimator and curve by treatment arm. Median invasive disease-free time will be given along with standard error. Comparison between arms will employ a log-rank test.","paramType":"MEDIAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.9569","spread":"0.0225"},{"groupId":"OG001","value":"3.4743","spread":"0.0298"}]}]}]},{"type":"SECONDARY","title":"Percent of Patients With Locoregional Recurrence","description":"The cumulative incidence of locoregional recurrence will be estimated using a competing risks method by treatment arm. The competing risks will be distant breast cancer recurrence and death. Comparison between arms will employ Fine-Gray regression. Locoregional recurrence is clinically diagnosed invasive breast cancer in the axilla, regional lymph nodes, chest wall, and/or skin of the ipsilateral breast at 5 years.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.3","spread":null},{"groupId":"OG001","value":"5.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Disease-Free Survival","description":"Will be estimated with a Kaplan-Meier estimator and curve by treatment arm. Median disease free survival time and standard error will be estimated. Comparison between arms will employ a log-rank test.","paramType":"MEDIAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.9569","spread":"0.0225"},{"groupId":"OG001","value":"3.17","spread":"0.0282"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Patient Reported Outcomes/Quality of Life","description":"The subscales of the Breast Cancer Treatment Outcomes Scale (BCTOS), elements from Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE), and other patient reported measures such as fatigue, breast pain, breast shape, and arm related morbidity outlined in the appendix will be summarized as the mean +/- standard deviation and median (minimum value, maximum value). Mixed models will be used to estimate changes at fixed time points.","paramType":null,"dispersionType":null,"classes":[]},{"type":"OTHER_PRE_SPECIFIED","title":"Patient Reported Outcomes/Quality of Life","description":"The subscales of the Breast Cancer Treatment Outcomes Scale (BCTOS), elements from Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE), and other patient reported measures such as fatigue, breast pain, breast shape, and arm related morbidity outlined in the appendix will be summarized as the mean +/- standard deviation and median (minimum value, maximum value). Mixed models will be used to compare outcomes between arms.","paramType":null,"dispersionType":null,"classes":[]},{"type":"OTHER_PRE_SPECIFIED","title":"Patient Self-reported Cosmesis","description":"Will evaluate fatigue, breast pain, arm function. The values of the cosmesis instruments (patient self-reported and panel-assessed) will be summarized with the frequencies and confidence intervals of fair or poor cosmesis events at baseline, 2 years, and 5 years by treatment arm. Comparisons between arms will employ chi-squared tests.","paramType":null,"dispersionType":null,"classes":[]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":54},"commonTop":["Dermatitis radiation","Skin hyperpigmentation","Pain","Lymphedema","Superficial soft tissue fibrosis"]}}}